Previous close | 6.75 |
Open | 5.70 |
Bid | 4.30 |
Ask | 6.50 |
Strike | 470.00 |
Expiry date | 2024-07-19 |
Day's range | 5.38 - 5.70 |
Contract range | N/A |
Volume | |
Open interest | 240 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.